Repligen Corporation (RGEN) exhibits 88.2% gross margins and 2.3% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 95.0x enterprise multiple and 4.8% implied options volatility.
Sustained 88.2% gross profitability converts into 1.8% operating margin and 2.3% ROIC, outpacing sector cost of capital.
ROIC: 2.3% // GM: 88.2%YoY revenue trajectory of -3.3% paired with 0.88% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -3.3% // FCF YLD: 0.88%Altman Z-Score of 9.31 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 9.31 // F-SCORE: 8/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 95.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $176.94 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 1.6% net margins.
NET MARGIN: 1.6% // D/E: 0.17x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for RGEN & activate live FRED threshold breach alerts.